Discontinuation rate of hormonal therapy in early stage breast cancer patients
Article Sidebar
Main Article Content
Abstract
Introduction: Five years of adjuvant hormonal therapy for estrogen receptor (ER)-positive breast cancer appears to improve survival in women with breast cancer. However, information on hormonal therapy discontinuation is scanty. The objective of this study was to investigate the discontinuation rate of hormonal therapy in early stage breast cancer patients in Thailand. Materials and Method: In this retrospective cohort study, data on medication therapy of patients diagnosed with early stage breast cancer (stage I-III) prescribed hormonal therapy at oncology center in Thailand between January 2004 and December 2009 were retrieved from medical records for review. Results: A total of 385 patients were recruited. Overall, 52 (13.5%) patients discontinued hormonal therapy before the completion of 5 years. Discontinuation rate was 52/1,405 person-years or 3.7/100 person-years of follow-up. The cumulative incidence of hormonal therapy discontinuation at 1, 2, 3, 4 and 5 years was 5.7%, 8.8%, 10.6%, 11.9% and 13.5%, respectively. Conclusion: Discontinuation rate of hormonal therapy in early stage breast cancer patients was 3.7/100 person-years and the highest rate was in the first year of treatment
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
World health organization [Internet]. [cited 2013 Nov 11]. Breast cancer prevention and control; [about 6 screens]. Available from: http://www.who.int/cancer/detection/breastcancer/en/index1.html
Barron TI, Connolly R, Bennett K, Feely J. and Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007 March 1; 109(5): 832–839.
Hershman DI, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010 September 20; 28(27): 4120-4128.
Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008 February 1; 26(4): 549–255.
Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W. and Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009 July 20; 27(21): 3445–3451.
Herk-Sukel MPP, Poll-Franse LV, Voogd, AC, Nieuwenhuijzen GAP, Coebergh, JWW, et al. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment perior of 5 years: a population-based analysis. Breast Cancer Res Treat. 2010; 122: 843-851.
Demissie S, Silliman RA. and Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontimnuation in older women. J Clin Oncol. 2001 January 15; 19(2): 322-328.
Bowles AJA, Boudreau DM, Chubak, J, Yu O, Fujii M, Chestnut J, et al. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Clin Oncol. 2012 November; 8(6): 149-157.